Companies › GCP-Service International West
2 active drug programs in 2 registered trials: 2 Phase 2; Hematology, Cardiovascular; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RVU120 (SEL120) CDK 8/19 inhibitor | CDKN2A | Phase 2 | Low Risk Myelodysplastic Syndromes | May 2027 |
| Omegaven® (Fish Oil) Intravenous fish oil emulsion providing long-chain n-3 polyunsaturated fatty acids (eicosa | – | Phase 2 | Intensive Care Unit | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06243458 | RVU120 (SEL120) | Phase 2 | Low Risk Myelodysplastic Syndromes | Hematology | May 2027 |
| NCT06279793 | Omegaven® (Fish Oil) | Phase 2 | Intensive Care Unit | Cardiovascular | Mar 2030 |
–
AllRock Bio Nyrada Zomagen Biosciences Agiana Pharmaceuticals Cardurion Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.